Evaluation of the clinical efficacy and safety of “Anti-Dandruff
... A baseline history was obtained in order to determine the patient’s eligibility for enrolment in the trial. The baseline assessment included personal data, a description of symptoms and details of past medical history (family history of dandruff and history of possible exacerbating factor/s). All th ...
... A baseline history was obtained in order to determine the patient’s eligibility for enrolment in the trial. The baseline assessment included personal data, a description of symptoms and details of past medical history (family history of dandruff and history of possible exacerbating factor/s). All th ...
Antimicrobial Stewardship and Long-Term Care (PDF: 542KB/36 pages)
... UTI: Treatment Considerations (cont.) • Antibiotic choice depends on several factors: • Local susceptibility data • Prior culture data and antibiotic use in the resident • Potential for drug interactions or side effects • Resident drug allergies • Reassess antibiotic therapy when susceptibilities a ...
... UTI: Treatment Considerations (cont.) • Antibiotic choice depends on several factors: • Local susceptibility data • Prior culture data and antibiotic use in the resident • Potential for drug interactions or side effects • Resident drug allergies • Reassess antibiotic therapy when susceptibilities a ...
... conformity to the properties evaluated for capsules. Pharmacological studies of polyherbal capsule were studied for its therapeutic efficacy, found safe up to 2000mg/kg body weight by acute toxicity study as per OECD guidelines and showed significant hepatoprotective activity at the doses of 200mg/k ...
Pharmacological strategies for detoxification
... fully informed of side effects (such as dysphoria, depression and insomnia) which may be due to the opioid withdrawal or to naltrexone itself. It is these side effects which lead to poor compliance and retention rates, as users will either stop taking the naltrexone or relapse. Many studies have emp ...
... fully informed of side effects (such as dysphoria, depression and insomnia) which may be due to the opioid withdrawal or to naltrexone itself. It is these side effects which lead to poor compliance and retention rates, as users will either stop taking the naltrexone or relapse. Many studies have emp ...
6_ARV_Drug_Toxicity
... • May lead to a reduction in the quality of life. • May be an important cause of non-adherence to therapy. REMEMBER: Overall experience in Botswana has shown that ARV medications are very well tolerated by the vast majority of patients! ...
... • May lead to a reduction in the quality of life. • May be an important cause of non-adherence to therapy. REMEMBER: Overall experience in Botswana has shown that ARV medications are very well tolerated by the vast majority of patients! ...
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS)
... Post operative nausea and vomiting (PONV) are considered as very unpleasant side effects of anaesthesia, causing distress and dissatisfaction to patients. It is multifactorial and despite advances in antiemetic therapy the incidence is high. The main patient related factors are age, gender, history ...
... Post operative nausea and vomiting (PONV) are considered as very unpleasant side effects of anaesthesia, causing distress and dissatisfaction to patients. It is multifactorial and despite advances in antiemetic therapy the incidence is high. The main patient related factors are age, gender, history ...
A Practical Guide to Dermatological Drug Use in Pregnancy
... B) have been considered the antihistamines of choice for oral and parenteral use, respectively, in pregnancy,20 although one case-control study showed an association between the use of diphenhydramine in the first trimester and cleft palate.21 Antihistamines in general have been linked to retrolenta ...
... B) have been considered the antihistamines of choice for oral and parenteral use, respectively, in pregnancy,20 although one case-control study showed an association between the use of diphenhydramine in the first trimester and cleft palate.21 Antihistamines in general have been linked to retrolenta ...
International Journal of Biomedical Research Review Article
... 2.1 Benzodiazepines13: Benzodiazepines are prescribed for short-term relief of severe and disabling anxiety. Benzodiazepines may also be indicated to cover the latent periods associated with the medications prescribed to treat an underlying anxiety disorder. They are used to treat a wide variety of ...
... 2.1 Benzodiazepines13: Benzodiazepines are prescribed for short-term relief of severe and disabling anxiety. Benzodiazepines may also be indicated to cover the latent periods associated with the medications prescribed to treat an underlying anxiety disorder. They are used to treat a wide variety of ...
NeuTropic™ Products - Biotics Research Corporation
... improve sperm quality5 and enhance male fertility6 by its action on the hypothalamus-pituitarygonadal axis. In addition to possessing antioxidant activity, Mucuna has been shown to demonstrate metal chelating activity, particularly iron.7 Practitioners commonly report that fibromyalgic patients resp ...
... improve sperm quality5 and enhance male fertility6 by its action on the hypothalamus-pituitarygonadal axis. In addition to possessing antioxidant activity, Mucuna has been shown to demonstrate metal chelating activity, particularly iron.7 Practitioners commonly report that fibromyalgic patients resp ...
Methadone Conversion Guideline
... to rotate opioids to methadone. (Our conversion table [Table 2.1] always requires that the equianalgesic amount of oral morphine be determined to calculate a daily dosage of methadone.) Step 1. Calculate the total daily oral morphine dosage. • Two tablets of 200 mg each, taken twice daily = 800 mg t ...
... to rotate opioids to methadone. (Our conversion table [Table 2.1] always requires that the equianalgesic amount of oral morphine be determined to calculate a daily dosage of methadone.) Step 1. Calculate the total daily oral morphine dosage. • Two tablets of 200 mg each, taken twice daily = 800 mg t ...
Targeting the trigeminal nerve system for orofacial pain treatment
... extends from the nostrils to the nasopharynx. The nasal cavity is divided into three primary regions: nasal vestibule, olfactory region and respiratory region. Turbinates are the bony structures that are covered by the vascularized mucosal tissue. These turbinates increase the surface area of the no ...
... extends from the nostrils to the nasopharynx. The nasal cavity is divided into three primary regions: nasal vestibule, olfactory region and respiratory region. Turbinates are the bony structures that are covered by the vascularized mucosal tissue. These turbinates increase the surface area of the no ...
What is a Clinical Trial Registry
... It depends on the individual protocol. The OHRP recommends that you allow at least 30 minutes for entering the protocol specific information. Which Clinical Trials should be Registered? The ICMJE wants to ensure public access to all "clinically directive" trials -- trials that test a clinical hypoth ...
... It depends on the individual protocol. The OHRP recommends that you allow at least 30 minutes for entering the protocol specific information. Which Clinical Trials should be Registered? The ICMJE wants to ensure public access to all "clinically directive" trials -- trials that test a clinical hypoth ...
Bulletin #94
... (a) For treatment of osteoporosis in patients who do not respond to etidronate disodium/calcium (Didrocal) after receiving it for 1 year. (b) For treatment of osteoporosis in patients unable to tolerate edironate disodium/calcium (Didrocal). infliximab, injection (mg), 100mg/vial (Remicade-SCH) Exce ...
... (a) For treatment of osteoporosis in patients who do not respond to etidronate disodium/calcium (Didrocal) after receiving it for 1 year. (b) For treatment of osteoporosis in patients unable to tolerate edironate disodium/calcium (Didrocal). infliximab, injection (mg), 100mg/vial (Remicade-SCH) Exce ...
Xyrem®, sodium oxybate, dru093
... 2. U.S. Xyrem Multicenter Study Group 1: Sodium oxybate demonstrates long-term efficacy for the treatment of cataplexy in patients with narcolepsy. Sleep Med 2004;5:119-23. 3. Anonymous. A 12-month, open-label, multicenter extension trial of orally administered sodium oxybate for the treatment of na ...
... 2. U.S. Xyrem Multicenter Study Group 1: Sodium oxybate demonstrates long-term efficacy for the treatment of cataplexy in patients with narcolepsy. Sleep Med 2004;5:119-23. 3. Anonymous. A 12-month, open-label, multicenter extension trial of orally administered sodium oxybate for the treatment of na ...
$doc.title
... and pediatric patients (3 years and older) with refractory partial seizures. Evidence of effectiveness was obtained in three trials conducted in 705 patients (age 12 years and above) and one trial conducted in 247 pediatric patients (3 to 12 years of age). The patients enrolled had a history of at l ...
... and pediatric patients (3 years and older) with refractory partial seizures. Evidence of effectiveness was obtained in three trials conducted in 705 patients (age 12 years and above) and one trial conducted in 247 pediatric patients (3 to 12 years of age). The patients enrolled had a history of at l ...
Comparative efficacy of inhaled albuterol between two handheld
... exacerbation, bronchoconstriction, airway wall oedema and accumulation of mucus result in obstruction of the distal airways. These mechanisms induce functional changes: maximum change in ...
... exacerbation, bronchoconstriction, airway wall oedema and accumulation of mucus result in obstruction of the distal airways. These mechanisms induce functional changes: maximum change in ...
2. qualitative and quantitative composition
... Polystyrene sulfonate (Kayexalate): Caution is advised when used concomitantly with polystyrene sulfonate (Kayexalate) due to the potential risks of reduced effectiveness of the resin in binding potassium, of metabolic alkalosis in patients with renal failure (reported with aluminium hydroxide and m ...
... Polystyrene sulfonate (Kayexalate): Caution is advised when used concomitantly with polystyrene sulfonate (Kayexalate) due to the potential risks of reduced effectiveness of the resin in binding potassium, of metabolic alkalosis in patients with renal failure (reported with aluminium hydroxide and m ...
PRESCRIBING GUIDELINES FOR PRIMARY CARE CLINICIANS
... These guidelines are intended to assist general practitioners (GPs) and other primary care clinicians to manage the complex medical, ethical and regulatory considerations involved in treating such patients, especially where there is exacerbation of chronic pain. There are several published guideline ...
... These guidelines are intended to assist general practitioners (GPs) and other primary care clinicians to manage the complex medical, ethical and regulatory considerations involved in treating such patients, especially where there is exacerbation of chronic pain. There are several published guideline ...
Advances in Environmental Biology
... rate of minimum, average and maximum were determined. In this way maximum dose was half of the lethal dose, medium-dose was half of maximum dose, and minimum dose was half of medium dose. Imipramine is a water-soluble drug. In this study, distilled water was used as solvent. All solutions were prepa ...
... rate of minimum, average and maximum were determined. In this way maximum dose was half of the lethal dose, medium-dose was half of maximum dose, and minimum dose was half of medium dose. Imipramine is a water-soluble drug. In this study, distilled water was used as solvent. All solutions were prepa ...
HyperGuide
... of cardiovascular disease and associated morbidity and mortality. The positive relationship between SBP and DBP and cardiovascular risk is well recognized. This relationship is significant for those with and without known coronary heart disease. To that end, it is useful to provide a classification ...
... of cardiovascular disease and associated morbidity and mortality. The positive relationship between SBP and DBP and cardiovascular risk is well recognized. This relationship is significant for those with and without known coronary heart disease. To that end, it is useful to provide a classification ...
Neuro-Oncology Practice - Oxford Academic
... Similarly to epilepsy in general, the diagnosis of BTRE is clinical and based on seizure semiology (what it looks like) and the experience reported by the patient (eg, auras). Patients with brain tumors are at a higher risk of epilepsy than the general population; therefore, the threshold for diagno ...
... Similarly to epilepsy in general, the diagnosis of BTRE is clinical and based on seizure semiology (what it looks like) and the experience reported by the patient (eg, auras). Patients with brain tumors are at a higher risk of epilepsy than the general population; therefore, the threshold for diagno ...
PRODUCT INFORMATION STOCRIN® (efavirenz) Tablets and Oral
... metabolites are essentially inactive against HIV-1. The in vitro studies suggest that CYP3A4 and CYP2B6 are the major isozymes responsible for efavirenz metabolism. In vitro studies have shown that efavirenz inhibited P450 isozymes 2C9, 2C19, and 3A4 with Ki values (8.517µM) in the range of observed ...
... metabolites are essentially inactive against HIV-1. The in vitro studies suggest that CYP3A4 and CYP2B6 are the major isozymes responsible for efavirenz metabolism. In vitro studies have shown that efavirenz inhibited P450 isozymes 2C9, 2C19, and 3A4 with Ki values (8.517µM) in the range of observed ...
Bilastine
Bilastine (trade name Bilaxten) is a second generation antihistamine drug for the treatment of allergic rhinoconjunctivitis and urticaria (hives).It exerts its effect as a selective histamine H1 receptor antagonist, and has a effectiveness similar to cetirizine, fexofenadine and desloratadine. It was developed in Spain by FAES Farma.Bilastine is approved in the European Union for the symptomatic treatment of allergic rhinoconjunctivitis and urticaria, but it is not approved by the U.S. Food and Drug Administration for any use in the United States. Bilastine meets the current European Academy of Allergy and Clinical Immunology (EAACI) and Allergic Rhinitis and its Impact of Asthma (ARIA) criteria for medication used in the treatment of allergic rhinitis.Bilastine has been effective in the treatment of ocular symptoms and diseases of allergies, including rhinoconjuctivitis. Additionally, bilastine has been shown to improve quality of life, and all nasal and ocular symptoms related to allergic rhinitis.